EUVIMEDEUVIMED entdecken
Crossref

Targeting an atypical G protein–coupled receptor signaling pathway for cardiac fibrosis therapy

Hao Zhang iD, Rabindra V Shivnaraine iD, Lu Ren iD, Phung N Thai iD, Remi Janicot, Wenjuan Zhu iD, Rihua Huang iD, Dirk H Siepe iD, Chengyi Tu, Wenqiang Liu iD, Marcin Maziarz, Jonathan C Deutsch iD und 10 weitere

Science · 24.09.2026 · 393 (6818)

DOI: 10.1126/science.aej5896 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science, erschienen am 24.09.2026. Verfasst von Hao Zhang und 21 weiteren Autor:innen. Beteiligte Einrichtung: Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA. Hauptthemen laut MEDLINE: Antifibrotic Agents, GTP-Binding Protein beta Subunits, GTP-Binding Protein gamma Subunits, Heart Failure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 121 Literaturangaben. Gefördert von: NIGMS NIH HHS, NHLBI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiac fibrosis independently predicts adverse outcomes in heart failure (HF), yet no Food and Drug Administration–approved therapy directly targets fibrotic remodeling in the heart. To address this unmet clinical need, we used a multidimensional drug discovery pipeline centered on a human induced pluripotent stem cell (iPSC)–based platform. Through high-throughput screening, we identified CGS15943 (CGS) as the lead antifibrotic compound and validated its activity in human cardiac fibroblasts, three-dimensional engineered heart tissues, and animal models of HF. Mechanistic studies revealed an atypical adenosine receptor (AR)–dependent signaling pathway in which AR subtypes converge on Gβγ (the βγ subunits of heterotrimeric GTP-binding proteins) to activate phosphoinositide 3-kinase (PI3K)–AKT and yes-associated protein (YAP). CGS suppressed this signaling axis, thereby reducing fibrotic gene expression and fibroblast activation. These findings establish AR-driven Gβγ signaling as a potential therapeutic target for cardiac fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifibrotic AgentsGTP-Binding Protein beta SubunitsGTP-Binding Protein gamma SubunitsHeart FailureMyocardiumReceptors, G-Protein-CoupledQuinazolinesTriazolesAdenosine A1 Receptor AntagonistsAdenosine A2 Receptor AntagonistsAnimalsHumansMiceFibroblastsFibrosisHigh-Throughput Screening AssaysInduced Pluripotent Stem CellsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionMaleFemaleMice, Inbred C57BLHEK293 CellsDisease Models, AnimalDrug Discovery

Substanzen

Antifibrotic AgentsGTP-Binding Protein beta SubunitsGTP-Binding Protein gamma SubunitsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktReceptors, G-Protein-Coupled9-chloro-2-(2-furyl)-(1,2,4)triazolo(1,5-c)quinazolin-5-imineQuinazolinesTriazolesAdenosine A1 Receptor Antagonists

Autor:innen und Institutionen

  • Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
  • Department of Physiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.
  • Greenstone Biosciences, Palo Alto, CA, USA.
  • Department of Internal Medicine, University of California, Davis, Davis, CA, USA.
  • Department of Biochemistry & Cell Biology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA, USA.

ORCID-Profile: Hao Zhang, Rabindra V Shivnaraine, Lu Ren, Phung N Thai, Wenjuan Zhu, Rihua Huang, Dirk H Siepe, Wenqiang Liu, Jonathan C Deutsch, Yu Liu, Chun Liu, Hyeonyu Kim, Mark Chandy, Marian Kalocsay, Nipavan Chiamvimonvat, Mikel Garcia-Marcos, Brian K Kobilka, Joseph C Wu

Förderung

  • NIGMS NIH HHS
  • NHLBI NIH HHS
  • NIAID NIH HHS
  • NCATS NIH HHS
  • NIA NIH HHS
  • NINDS NIH HHS
  • National Institutes of Health
  • American Heart Association

Zitieren

APA

Zhang, H., Shivnaraine, R. V., Ren, L., Thai, P. N., Janicot, R., Zhu, W., Huang, R., Siepe, D. H., Tu, C., Liu, W., Maziarz, M., Deutsch, J. C., Liu, Y., Liu, C., Shin, D. H., Kim, H., Chandy, M., Kalocsay, M., Chiamvimonvat, N., …, & Wu, J. C. (2026). Targeting an atypical G protein–coupled receptor signaling pathway for cardiac fibrosis therapy. Science, 393(6818). https://doi.org/10.1126/science.aej5896

Vancouver

Zhang H, Shivnaraine RV, Ren L, Thai PN, Janicot R, Zhu W, et al. Targeting an atypical G protein–coupled receptor signaling pathway for cardiac fibrosis therapy. Science. 2026;393(6818). doi:10.1126/science.aej5896

BibTeX
@article{Zhang2026,
  author = {Zhang, Hao and Shivnaraine, Rabindra V and Ren, Lu and Thai, Phung N and Janicot, Remi and Zhu, Wenjuan and Huang, Rihua and Siepe, Dirk H and Tu, Chengyi and Liu, Wenqiang and Maziarz, Marcin and Deutsch, Jonathan C and Liu, Yu and Liu, Chun and Shin, Danielle H and Kim, Hyeonyu and Chandy, Mark and Kalocsay, Marian and Chiamvimonvat, Nipavan and Garcia-Marcos, Mikel and Kobilka, Brian K and Wu, Joseph C},
  title = {Targeting an atypical G protein–coupled receptor signaling pathway for cardiac fibrosis therapy},
  journal = {Science},
  year = {2026},
  volume = {393},
  number = {6818},
  doi = {10.1126/science.aej5896}
}
Kostenlos starten →